Nemaura Medical

117 articles about Nemaura Medical

• Nemaura Includes Insulin on List of Drugs Eligible for EU DuoPack License Agreement

  3/15/2023

  Nemaura Medical, Inc. announced that it now includes insulin on the list of drugs under the DuoPack Commercial License Agreement with its licensee, MySugarWatch DuoPack Limited.

• Nemaura Medical Announces Receipt of Notice from Nasdaq

  3/9/2023

  Nemaura Medical, Inc. today announced that on February 23, 2023, the Company was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) as a result of its failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2022.

• Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update

  2/24/2023

  Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs, today releases its financial results for the quarter ending December 31, 2022 and provides a business update.

• Nemaura Medical to Participate in Fireside Chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Virtual Conference

  2/16/2023

  Nemaura Medical, Inc. announces that CEO Dr. Faz Chowdhury will participate in a fireside chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Conference that is being held virtually on February 21 – 24, 2023.

• Nemaura Medical Announces Closing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement

  1/31/2023

  Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”) today announced the close of its previously announced registered direct offering (the “Registered Direct Offering”) with two healthcare-focused U.S. institutional investors to sell 4,796,206 shares of its common stock (the “Shares”) and warrants to purchase up to 4,796,206 Shares (the “Warrants”), in a concurrent private placement (the “Private Placement”).

• Nemaura Medical Announces Pricing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement

  1/27/2023

  Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”) today announced it has entered into a definitive agreement with two healthcare-focused U.S. institutional investors to sell 4,796,206 shares of its common stock (the “Shares”), pursuant to a registered direct offering (the “Registered Direct Offering”), and warrants to purchase up to 4,796,206 Shares (the “Warrants”), in a concurrent private placement (the “Private Placement”).

• Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants

  1/24/2023

  Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs, announces initial results from patient studies of its metabolic health program Miboko with the National Health Service (NHS) in the United Kingdom.

• Nemaura Medical to Present at the Sidoti & Co. Micro Cap Virtual Conference

  1/11/2023

  Nemaura Medical, Inc. announces that CEO Dr. Faz Chowdhury will present a corporate overview at the Sidoti & Co. Micro Cap Virtual Conference being held on January 18 -19, 2023.

• Nemaura Medical to Present at the Planet MIcroCap Showcase: Virtual 2022

  12/1/2022

  Nemaura Medical, Inc. announces today that CEO Dr. Faz Chowdhury will present a corporate overview at the Planet MicroCap Showcase: Virtual 2022 being held on December 6 – 8, 2022.

• Nemaura Medical Reports Fiscal Second Quarter 2023 Results and Provides Business Update

  11/15/2022

  Nemaura Medical, Inc. today releases its financial results for the quarter ending September 30, 2022 and provides a business update.

• Nemaura Medical to Present at the Bernstein 2ND Annual CGM Disruptors Conference

  11/11/2022

  Nemaura Medical, Inc. announces today that CEO Dr. Faz Chowdhury will present a corporate overview at at the Bernstein 2nd Annual CGM Disruptors Conference which is being held virtually on November 18, 2022.

• Nemaura Receives Provisional Purchase Order from Middle East Licensee TPMENA

  10/12/2022

  Nemaura Medical, Inc. announced it has received a provisional purchase order from TPMENA, its MENA licensee for the Company’s sugarBEAT® system.

• Nemaura Medical to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference

  10/4/2022

  Nemaura Medical, Inc. announces that CEO Dr. Faz Chowdhury will present a corporate overview at at the MicroCap Rodeo Windy City Roundup 2022 Conference.

• Nemaura and EVERSANA sign preliminary agreement for large-scale launch of Nemaura’s Diabetes Management Program in the U.S.

  9/27/2022

  Nemaura Medical, Inc. announces that it has entered into a preliminary agreement with EVERSANA®, a pioneer of next-generation commercial services to the global life sciences industry.

• Nemaura Medical to Present at the 24th Annual H.C. Wainwright Global Investment Conference

  9/6/2022

  Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at the 24th Annual H.C. Wainwright Global Investment Conference.

• Nemaura Medical Reports Fiscal First Quarter 2023 Results and Provides Business Update

  8/15/2022

  Nemaura Medical, Inc. today releases its financial results for the quarter ending June 30, 2022 and provides a business update.

• Nemaura Medical Granted UK Trademark “Meta Score,” a Digital Biomarker Term for its Metabolic Health Program

  7/21/2022

  Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), today announced that it has been granted a UK trademark for “Meta Score,” a term the Company plans to use as a digital biomarker for its consumer metabolic health program.

• Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2022

  6/30/2022

  Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the fiscal year ended March 31, 2022.

• Nemaura Medical Strengthens Balance Sheet with Further Non-Dilutive Funding

  5/23/2022

  Nemaura Medical, Inc., a medical technology company focused on commercializing a daily disposable wearable glucose sensor and supporting personalized digital coaching programs, announces that it has secured $5 million in non-dilutive funding though a clean debt facility with no warrants or convertible elements.

• Nemaura Medical to Present at the H.C. Wainwright Global Hybrid Investment Conference

  5/19/2022

  Nemaura Medical, Inc. announces that CEO Dr. Faz Chowdhury will present virtually at the H.C. Wainwright Global Hybrid Investment Conference.